Patient survival by molecular subgroup in each of the three series was consistent with previous published reports [5, 12]; specifically, patients with triple-positive tumours had the best prognosis whilst those with TERT-only tumours had the worst outcome (Supplementary Fig. 3 [Online Resource 1]). This evidence concerns the gene TERT and neoplasm.